Surgical risk reduction: Prophylactic salpingo-oophorectomy and prophylactic mastectomy

American Journal of Obstetrics and Gynecology

Volumn 191, Issue 4, 2004, Pages 1113-1123

  Dowdy, Sean C ^a   Stefanek, Michael ^b   Hartmann, Lynn C ^c  

^a MAYO CLINIC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MAYO CLINIC CANCER CENTER   (United States)

Author keywords

Breast cancer; Mastectomy; Oophorectomy; Ovarian cancer; Prophylactic

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CYTOTOXIC AGENT; ESTROGEN; ORAL CONTRACEPTIVE AGENT; PACLITAXEL; PLATINUM DERIVATIVE; PROGESTERONE; TAMOXIFEN;

ANAMNESIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER FAMILY; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; ESTHETICS; ESTROGEN DEFICIENCY; GENE MUTATION; GERM LINE; HETEROZYGOTE; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; LAPAROSCOPIC SURGERY; MAMMOGRAPHY; MASTECTOMY; MEDICAL DECISION MAKING; MENOPAUSAL SYNDROME; OVARY CANCER; PERITONEUM CANCER; PHYSICIAN; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY; SOCIAL PSYCHOLOGY; SURGICAL RISK; SURGICAL TECHNIQUE;

EID: 7044264641     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2004.04.028     Document Type: Article

References (73)

1. King M.C., Marks J.H., Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 302:2003;643-646
2. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer statistics, 2004. CA Cancer J Clin. 54:2004;8-29
3. Warner E., Plewes D.B., Shumak R.S., Catzavelos G.C., Di Prospero L.S., Yaffe M.J., et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol. 19:2001;3524-3531
4. Morris E.A. Screening for breast cancer with MRI. Semin Ultrasound CT MR. 24:2003;45-54
5. Modugno F. Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. Gynecol Oncol. 91:2003;15-31
6. Cuzick J., Powles T., Veronesi U., Forbes J., Edwards R., Ashley S., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 361:2003;296-300
7. Chlebowski R.T., Col N., Winer E.P., Collyar D.E., Cummings S.R., Vogel V.G. 3rd, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 20:2002;3328-3343
8. Brekelmans C.T., Seynaeve C., Bartels C.C., Tilanus-Linthorst M.M., Meijers-Heijboer E.J., Crepin C.M., et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol. 19:2001;924-930
9. Loman N., Johannsson O., Bendahl P.O., Borg A., Ferno M., Olsson H. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer. 83:1998;310-319
10. Lakhani S.R., Van De Vijver M.J., Jacquemier J., Anderson T.J., Osin P.P., McGuffog L., et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 20:2002;2310-2318
11. Narod S.A., Risch H., Moslehi R., Dorum A., Neuhausen S., Olsson H., et al. Oral contraceptives and the risk of hereditary ovarian cancer: Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med. 339:1998;424-428
12. Bosetti C., Negri E., Trichopoulos D., Franceschi S., Beral V., Tzonou A., et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer. 102:2002;262-265
13. Averette H.E., Hoskins W., Nguyen H.N., Boike G., Flessa H.C., Chmiel J.S., et al. National survey of ovarian carcinoma: I, patient care evaluation study of the American College of Surgeons. Cancer. 71:(Suppl):1993;1629-1638
14. Sightler S.E., Boike G.M., Estape R.E., Averette H.E. Ovarian cancer in women with prior hysterectomy: a 14-year experience at the University of Miami. Obstet Gynecol. 78:1991;681-684
15. Tobacman J.K., Greene M.H., Tucker M.A., Costa J., Kase R., Fraumeni J.F. Jr. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet. 2:1982;795-797
16. Struewing J.P., Watson P., Easton D.F., Ponder B.A., Lynch H.T., Tucker M.A. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr. 17:1995;33-35
17. Bloodgood J.C. The remaining breast after radical removal of the opposite side for carcinoma. Trans Southern Surg Assoc. 34:1921;223-241
18. Hicken N.F. Mastectomy: clinical pathologic study demonstrating why most mastectomies result in incomplete removal of the mammary gland. Arch Surg. 40:1940;6-12
19. Ziegler L.D., Kroll S.S. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol. 14:1991;451-454
20. Eldar S., Meguid M.M., Beatty J.D. Cancer of the breast after prophylactic subcutaneous mastectomy. Am J Surg. 148:1984;692-693
21. Goodnight J.E. Jr., Quagliana J.M., Morton D.L. Failure of subcutaneous mastectomy to prevent the development of breast cancer. J Surg Oncol. 26:1984;198-201
22. Wong J.H., Jackson C.F., Swanson J.S., Palmquist M.A., Oyama A.A., Miller S.H., et al. Analysis of the risk reduction of prophylactic partial mastectomy in Sprague-Dawley rats with 7, 12-dimethylbenzanthracene-induced breast cancer. Surgery. 99:1986;67-71
23. Moslehi R., Chu W., Karlan B., Fishman D., Risch H., Fields A., et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet. 66:2000;1259-1272
24. Boyd J., Sonoda Y., Federici M.G., Bogomolniy F., Rhei E., Maresco D.L., et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 283:2000;2260-2265
25. Rebbeck T.R., Levin A.M., Eisen A., Snyder C., Watson P., Cannon-Albright L., et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 91:1999;1475-1479
26. Fisher E.R., Fisher B., Sass R., Wickerham L. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol No. 4): XI, bilateral breast cancer. Cancer. 54:1984;3002-3011
27. Piver M.S., Jishi M.F., Tsukada Y., Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: a report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer. 71:1993;2751-2755
28. Kauff N.D., Satagopan J.M., Robson M.E., Scheuer L., Hensley M., Hudis C.A., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 346:2002;1609-1615
29. Rebbeck T.R., Lynch H.T., Neuhausen S.L., Narod S.A., Van't Veer L., Garber J.E., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 346:2002;1616-1622
30. Colgan T.J., Murphy J., Cole D.E., Narod S., Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 25:2001;1283-1289
31. Leeper K., Garcia R., Swisher E., Goff B., Greer B., Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 87:2002;52-56
32. Lu K.H., Garber J.E., Cramer D.W., Welch W.R., Niloff J., Schrag D., et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol. 18:2000;2728-2732
33. Hartmann L.C., Schaid D.J., Woods J.E., Crotty T.P., Myers J.L., Arnold P.G., et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 340:1999;77-84
34. Gail M.H., Brinton L.A., Byar D.P., Corle D.K., Green S.B., Schairer C., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 81:1989;1879-1886
35. Stefanek M., Hartmann L., Nelson W. Risk-reduction mastectomy: clinical issues and research needs. J Natl Cancer Inst. 93:2001;1297-1306
36. Hartmann L.C., Sellers T.A., Schaid D.J., Frank T.S., Soderberg C.L., Sitta D.L., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 93:2001;1633-1637
37. Meijers-Heijboer H., van Geel B., van Putten W.L., Henzen-Logmans S.C., Seynaeve C., Menke-Pluymers M.B., et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 345:2001;159-164
38. Aziz S., Kuperstein G., Rosen B., Cole D., Nedelcu R., McLaughlin J., et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol. 80:2001;341-345
39. Brose M.S., Rebbeck T.R., Calzone K.A., Stopfer J.E., Nathanson K.L., Weber B.L. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 94:2002;1365-1372
40. Paley P.J., Swisher E.M., Garcia R.L., Agoff S.N., Greer B.E., Peters K.L., et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol. 80:2001;176-180
41. Bilimoria M.M., Morrow M. The woman at increased risk for breast cancer: evaluation and management strategies. CA Cancer J Clin. 45:1995;263-278
42. Woods J.E. Subcutaneous mastectomy: current state of the art. Ann Plast Surg. 11:1983;541-550
43. Newman L.A., Kuerer H.M., Hung K.K., Vlastos G., Ames F.C., Ross M.I., et al. Prophylactic mastectomy. J Am Coll Surg. 191:2000;322-330
44. Swisher E.M., Babb S., Whelan A., Mutch D.G., Rader J.S. Prophylactic oophorectomy and ovarian cancer surveillance: patient perceptions and satisfaction. J Reprod Med. 46:2001;87-94
45. Anasti J.N., Kalantaridou S.N., Kimzey L.M., Defensor R.A., Nelson L.M. Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol. 91:1998;12-15
46. Shapiro C.L., Manola J., Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 19:2001;3306-3311
47. Aitken J.M., Hart D.M., Anderson J.B., Lindsay R., Smith D.A., Speirs C.F. Osteoporosis after oophorectomy for non-malignant disease in premenopausal women. BMJ. 2:1973;325-328
48. Saarto T., Blomqvist C., Valimaki M., Makela P., Sarna S., Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol. 15:1997;1341-1347
49. Bruschi F., Meschia M., Soma M., Perotti D., Paoletti R., Crosignani P.G. Lipoprotein(a) and other lipids after oophorectomy and estrogen replacement therapy. Obstet Gynecol. 88:1996;950-954
50. Suda Y., Ohta H., Makita K., Takamatsu K., Horiguchi F., Nozawa S. Influence of bilateral oophorectomy upon lipid metabolism. Maturitas. 29:1998;147-154
51. Saarto T., Blomqvist C., Ehnholm C., Taskinen M.R., Elomaa I. Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer. J Clin Endocrinol Metab. 81:1996;4453-4457
52. Kritz-Silverstein D., Barrett-Connor E., Wingard D.L. Hysterectomy, oophorectomy, and heart disease risk factors in older women. Am J Public Health. 87:1997;676-680
53. Colditz G.A., Willett W.C., Stampfer M.J., Rosner B., Speizer F.E., Hennekens C.H. Menopause and the risk of coronary heart disease in women. N Engl J Med. 316:1987;1105-1110
54. Belchetz P.E. Hormonal treatment of postmenopausal women. N Engl J Med. 330:1994;1062-1071
55. Nelson H.D., Humphrey L.L., Nygren P., Teutsch S.M., Allan J.D. Postmenopausal hormone replacement therapy: scientific review. JAMA. 288:2002;872-881
56. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333
57. Eisen A., Rebbeck T.R., Wood W.C., Weber B.L. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol. 18:2000;1980-1995
58. Bairey Merz C.N., Olson M.B., Johnson B.D., Bittner V., Hodgson T.K., Berga S.L., et al. Cholesterol-lowering medication, cholesterol level, and reproductive hormones in women: the Women's Ischemia Syndrome Evaluation (WISE). Am J Med. 113:2002;723-727
59. Lobo R.A., Cassidenti D.L. Pharmacokinetics of oral 17 beta-estradiol. J Reprod Med. 37:1992;77-84
60. Gabriel S.E., Woods J.E., O'Fallon W.M., Beard C.M., Kurland L.T., Melton L.J. 3rd. Complications leading to surgery after breast implantation. N Engl J Med. 336:1997;677-682
61. Sakorafas G.H., Tsiotou A.G. Prophylactic mastectomy; evolving perspectives. Eur J Cancer. 36:2000;567-578
62. Zion S.M., Slezak J.M., Sellers T.A., Woods J.E., Arnold P.G., Petty P.M., et al. Reoperations after prophylactic mastectomy with or without implant reconstruction. Cancer. 98:2003;2152-2160
63. Scheuer L., Kauff N., Robson M., Kelly B., Barakat R., Satagopan J., et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 20:2002;1260-1268
64. Lerman C., Hughes C., Croyle R.T., Main D., Durham C., Snyder C., et al. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med. 31:2000;75-80
65. Evans D., Lalloo F., Shenton A., Boggis C., Howell A. Uptake of screening and prevention in women at very high risk of breast cancer. Lancet. 358:2001;889-890
66. Meijers-Heijboer E.J., Verhoog L.C., Brekelmans C.T., Seynaeve C., Tilanus-Linthorst M.M., Wagner A., et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet. 355:2000;2015-2020
67. Fry A., Rush R., Busby-Earle C., Cull A. Deciding about prophylactic oophorectomy: What is important to women at increased risk of ovarian cancer? Prev Med. 33:2001;578-585
68. Miller S.M., Fang C.Y., Manne S.L., Engstrom P.F., Daly M.B. Decision making about prophylactic oophorectomy among at-risk women: psychological influences and implications. Gynecol Oncol. 75:1999;406-412
69. Tiller K., Meiser B., Butow P., Clifton M., Thewes B., Friedlander M., et al. Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer: a prospective study. Gynecol Oncol. 86:2002;212-219
70. Fry A., Busby-Earle C., Rush R., Cull A. Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. Psychooncology. 10:2001;231-241
71. Meiser B., Tiller K., Gleeson M.A., Andrews L., Robertson G., Tucker K.M. Psychological impact of prophylactic oophorectomy in women at increased risk for ovarian cancer. Psychooncology. 9:2000;496-503
72. Frost M.H., Schaid D.J., Sellers T.A., Slezak J.M., Arnold P.G., Woods J.E., et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA. 284:2000;319-324
73. Hatcher M.B., Fallowfield L., A'Hern R. The psychosocial impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured interviews. BMJ. 322:2001;76